Model Medicines
La Jolla, US · Founded 2019 · Delaware corporation · 15 employees on LinkedIn · 5 known investors
Find your way into Model Medicines
2,280 people in our graph share verified history with the Model Medicines team — schools, employers, funds. One of them is your warm intro.
Kyle Dohertyunlockedknows Daniel Haders · together at Harvard Business School (overlapped)
×3knows the team · via Stanford University
knows the team · via Harvard Business School
knows the team · via AT&T
×2knows the team · via University of Oxford
×2knows the team · via Oracle
Model Medicines is an AI-powered biotechnology company that uses computation to discover and engineer small molecule drugs targeting disease-driving biological mechanisms. The company has programs in infectious disease, oncology, and inflammation, with compounds in development including a broad-spectrum antiviral and a BRD4 inhibitor.
Founders & leadership
Model Medicines was founded in 2019 by Daniel Haders, Daniel Haders II, Ph.D, and Sean Russell.
DH
Daniel Hadersin𝕏Co-Founder, Board Director, Executive ChairmanDaniel Haders holds a PhD in Biomedical Engineering and serves as Co-Founder and CEO of Model Medicines, an AI-driven biotechnology company developing small-molecule therapeutics. Previously, he launched a digital health accelerator managing a portfolio of early-stage healthcare companies and served as an operating partner in venture capital advising on digital health investments.
DH
Daniel Haders II, Ph.Din𝕏Co-Founder, Board Director, Executive ChairmanDaniel Haders II holds a Ph.D. and BS in Biomedical Engineering and previously led a digital health accelerator managing a portfolio of 25+ early-stage healthcare companies and serving as an operating partner in venture capital advising on digital health investments. He is now founder and CEO of Model Medicines, an AI-driven biotechnology company developing small molecule therapeutics.
SR
Sean RussellinCo-founder, Chief Operating Officer and Head of Discovery, Research and DevelopmentSean Russell has over 20 years of drug development experience, having overseen more than 20 INDs and 12 NDAs that contributed to the approval of multiple therapies across CNS, infectious disease, women's health, and autoimmune indications. He is Chief Operating Officer at Model Medicines, an AI-powered biotech company developing small molecule drugs through its proprietary GALILEO platform.
KQ
Kip QuackenbushinMember Board Of Directors2019–2024Kip Quackenbush has held executive leadership roles in enterprise software and SaaS companies including Oracle, Commerce One, Akonix, Red Condor, Edgewave, ProfitLine, Sendio, Accelerate IT Advisors, and Nex Cubed, managing teams and revenue targets across various scales.
ME
Marlon EvansinBoard Member2019–2024Marlon Evans has held executive leadership roles spanning higher education, nonprofit organizations, Fortune 500 companies, venture capital, and startups, with over 15 years of experience as a CEO or Executive Director.
Investors · 5
8VCAustin · $100K – $50M
ParticleHong Kong · $1M – $6.9M
Irving InvestorsreportedNew York
Nex CubedreportedLa Jolla
Also in the syndicate · 1
Particle X
Funding
SEC filings, press & company announcements$26.6M disclosed across 5 rounds · 2020–2025
- $4.1MraisedNov 2021 · 2 sources
8VC, Irving Investors, Nex Cubed, Particle X
Source ↗
▶$3.3MraisedNov 2025 · 10 investors · OtherRule 506(b)
▶$3.3MraisedNov 2025 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Daniel HadersExecutive Officer
- Offering amount
- $5M
- Amount sold
- $3.3M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.8MraisedOct 2024 · 43 investors · BiotechnologyRule 506(b)
▶$14.8MraisedOct 2024 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kip QuackenbushExecutive Officer, Director
- Daniel HadersExecutive Officer, Director
- Marlon EvansExecutive Officer, Director
- Amount sold
- $14.8M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$950KraisedFeb 2024 · 10 investors · BiotechnologyRule 506(b)
▶$950KraisedFeb 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel HadersExecutive Officer, Director
- Marlon EvansExecutive Officer, Director
- Kip QuackenbushExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $950K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$3.5MraisedNov 2021 · 5 investors · Other TechnologyRule 506(b)
▶$3.5MraisedNov 2021 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Kip QuackenbushExecutive Officer, Director
- Marlon EvansExecutive Officer, Director
- Daniel HadersExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Model Medicines for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Model Medicines do?
- Model Medicines is an AI-powered biotechnology company that uses computation to discover and engineer small molecule drugs targeting disease-driving biological mechanisms. The company has programs in infectious disease, oncology, and inflammation, with compounds in development including a broad-spectrum antiviral and a BRD4 inhibitor.
- Who founded Model Medicines?
- Model Medicines was founded by Daniel Haders, Daniel Haders II, Ph.D, Sean Russell in 2019.
- Who are Model Medicines's investors?
- Model Medicines's investors include 8VC, Particle, Irving Investors, Nex Cubed.
- How much funding has Model Medicines raised?
- Model Medicines has disclosed $26.6M raised across 5 rounds.
- Where is Model Medicines headquartered?
- Model Medicines is headquartered in La Jolla, US.